Aktis Oncology, Inc. Overview
Industry: Biotechnology: Pharmaceutical Preparations
Sector: Health Care
Aktis Oncology is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. We see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope. To ensure patient demand is reliably met, we are also establishing efficient end-to-end supply, with a combination of critical internal capabilities paired with established external vendors. Through these efforts, we seek to maximize clinical utility across multiple indications in multiple tumor types, and to expand the commercial uptake of radiopharmaceuticals beyond the traditional nuclear medicine setting and into the more expansive clinical oncology setting. Aktis Oncology is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. We see a significant opportunity to broaden the cancer patient populatio Read More
Newly listed company coverage
Verified company profile, price history, and SEC registration source are available.
Review the SEC registration filingMavefund brings filings, fundamentals, valuation, price history and news for Aktis Oncology, Inc. into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $3.4M (+112% YoY). Net loss was -$24.1M (from $18.1M). R&D expense was $25.3M.
Revenue
$3.4M
+112% YoY
Net loss
-$24.1M
from $18.1M
R&D expense
$25.3M
reported
G&A expense
$7M
reported
What changed
- Revenue +112% YoY to $3.4M.
- Net loss was -$24.1M (from $18.1M).
Guidance / outlook
we expect to initiate the Phase 1b trial with AKY-2519 in B7-H3 expressing solid tumors, representing our third Phase 1b trial.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
AKTS260821P00022500 interactive stock chart | AKTS Aug 2026 22.500 put stock
Headline from Yahoo Finance Singapore: AKTS260821P00022500 interactive stock chart | AKTS Aug 2026 22.500 put stock.
AKTS Aug 2026 25.000 call (AKTS260821C00025000) interactive stock chart – Yahoo Finance
Headline from Yahoo Finance Singapore: AKTS Aug 2026 25.000 call (AKTS260821C00025000) interactive stock chart – Yahoo Finance.
Earnings Per Share
Score 2.00/5
Aktis Oncology, Inc. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Propanc Biopharma, Inc.
Shoulder Innovations, Inc.
In
Biotechnology: Pharmaceutical Preparations industry
, Propanc Biopharma, Inc.
, Ascentage Pharma Group International
, Aardvark Therapeutics, Inc.
are companies with high ratings.
Return on Equity
Score 0.00/5
Aktis Oncology, Inc. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Propanc Biopharma, Inc.
Shoulder Innovations, Inc.
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 0.00/5
Aktis Oncology, Inc.
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Propanc Biopharma, Inc.
Shoulder Innovations, Inc.
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 1.00/5
Aktis Oncology, Inc.
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Propanc Biopharma, Inc.
Shoulder Innovations, Inc.
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios